Axsome Therapeutics's three largest insider shareholders as of March 23, 2026 are Mark Coleman (Director, 403.86K shares), Roger Jeffs (Director, 57.51K shares), Mark Coleman (Director, 47.14K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Mark Coleman | 0 | 403,856 | 15 Sep, 2023 | |
| Roger Jeffs | 57,510 | 0 | 02 Sep, 2025 | |
| Mark Coleman | 47,140 | 0 | 27 Feb, 2026 | |
| Nick Pizzie | Chief Financial Officer | 42,588 | 0 | 23 Jan, 2026 |
| Mark E Saad | 10,002 | 0 | 02 Jan, 2026 | |
| Herriot Tabuteau | Chief Executive Officer | 7,229 | 0 | 02 Feb, 2026 |
| Nick Pizzie | Chief Financial Officer | 0 | 142 | 22 Nov, 2021 |
| Mark E Saad | 0 | 100 | 19 Nov, 2021 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 26 Feb, 2026 | Hunter R. Murdock | Restricted Stock Units | A | 16,385 | $0.00 | 16,385 | D | A |
| 26 Feb, 2026 | Herriot Tabuteau | Restricted Stock Units | A | 54,623 | $0.00 | 54,623 | D | A |
| 26 Feb, 2026 | Mark L. Jacobson | Common Stock | A | 35,378 | $2.85 | 35,378 | D | M |
| 26 Feb, 2026 | Mark L. Jacobson | Restricted Stock Units | A | 19,663 | $0.00 | 19,663 | D | A |
| 26 Feb, 2026 | Nick Pizzie | Restricted Stock Units | A | 18,570 | $0.00 | 18,570 | D | A |
| 26 Feb, 2026 | Mark Coleman | Common Stock | D | 25,000 | $161.11 | 47,140 | D | S |
| 26 Feb, 2026 | Ari Maizel | Restricted Stock Units | A | 16,385 | $0.00 | 16,385 | D | A |
| 26 Feb, 2026 | Mark L. Jacobson | Common Stock | D | 35,378 | $161.88 | 0 | D | S |
| 26 Feb, 2026 | Mark L. Jacobson | Stock Option (Right to Buy) | D | 35,378 | $0.00 | 0 | D | M |
| 23 Feb, 2026 | Mark Coleman | Common Stock | A | 6,250 | $4.95 | 72,140 | D | M |
| 23 Feb, 2026 | Mark Coleman | Stock Option (Right to Buy) | D | 6,250 | $0.00 | 7,721 | D | M |
| 20 Feb, 2026 | Mark Coleman | Common Stock | A | 12,485 | $4.95 | 65,890 | D | M |
| 20 Feb, 2026 | Mark Coleman | Stock Option (Right to Buy) | D | 12,485 | $0.00 | 13,971 | D | M |
| 10 Feb, 2026 | Mark Coleman | Common Stock | A | 5,193 | $8.02 | 53,405 | D | M |
| 10 Feb, 2026 | Mark Coleman | Stock Option (Right to Buy) | D | 5,193 | $0.00 | 0 | D | M |
| 02 Feb, 2026 | Herriot Tabuteau | Common Stock | A | 32,410 | $8.02 | 39,639 | D | M |
| 02 Feb, 2026 | Herriot Tabuteau | Common Stock | D | 32,410 | $185.60 | 7,229 | D | S |
| 02 Feb, 2026 | Herriot Tabuteau | Stock Option (Right to Buy) | D | 32,410 | $0.00 | 0 | D | M |
| 21 Jan, 2026 | Ari Maizel | Common Stock | A | 7,500 | $70.73 | 7,500 | D | M |
| 22 Jan, 2026 | Nick Pizzie | Common Stock | A | 12,000 | $3.50 | 54,588 | D | M |